NR3C1 and breast carcinoma: We tested the Tfsitescan predictions by treating cultured representative breast cancer cell line, MDA MB 231, for 24 h with known activators for NFκB (TNF-α), NFAT (PMA or ionomycin), GR (dexamethasone), and AP1 (PMA) and measuring the levels of each mRNA by qRT-PCR.